Objective: Patients with locally advanced head and neck cancer were treated with concurrent chemoradiotherapy using three courses of cisplatin. However, many patients were unable to complete the scheduled cisplatin treatment due to adverse effects. The objective of this study was to retrospectively elucidate the source of the low completion rate of cisplatin courses. Methods: Between November 2007 and 28 May 2010, patients with head and neck cancer were treated with curative intent according to the concurrent chemoradiotherapy protocol (66-70 Gy at 2 Gy/day with cisplatin 80 mg/m 2 on Days 1, 22 and 43). Treatment courses, hematological data and other parameters were investigated, and the treatment completion rates and reasons for treatment failure were analyzed. Results: Among the 28 patients, cisplatin was administered during the period of radiotherapy a total of 3 times in 9 (32%) patients, 2 times in 15 (54%) patients and only 1 time in 4 (14%) patients. Multiple regression analysis of the development of neutropenia at 3 weeks after the first cisplatin administration revealed that the serum albumin level was a significant explanatory variable (R 2 ¼ 0.664, b ¼ 0.517, P , 0.01). Pearson's product-moment correlation coefficient showed a strong correlation between the serum albumin level and the neutrophil count after 3 weeks (r ¼ 0.605, P , 0.01). Conclusions: The treatment completion rate by this protocol was low in head and neck cancer patients even when the cisplatin dose was reduced to 80 mg/m 2 . This tendency was seen in patients with a low serum albumin level.
INTRODUCTION
Anticancer agents are often administered concurrently with radiotherapy to improve the rates of organ preservation and local disease control in patients with head and neck cancers that are locally advanced (Stage III or IV) and unresectable, or in patients who refuse surgery [1, 2] . Many clinical studies have shown that concurrent chemoradiotherapy improves therapeutic efficacy for local advanced head and neck cancers compared with radiotherapy alone [3 -5] . Furthermore , it has been demonstrated that the therapeutic effect is greater when the chemotherapy and radiotherapy are administered concurrently rather than at different times [6, 7] . Combined chemoradiotherapy presents some problems, however, with more severe adverse events, resulting in a reduced treatment completion rate [8] . In numerous randomized clinical studies in various countries, although the usefulness of the treatment was demonstrated, the completion rate was only 53 -70% for a treatment protocol that are called for the administration of three courses of 100 mg/m At the department of Otorhinolaryngology of Nagoya University Hospital, patients with advanced head and neck cancer were treated with concurrent chemoradiotherapy consisting of radiotherapy at 2 Gy/day, 5 days/week, to a total dose of 66 -70 Gy, in combination with cisplatin 80 mg/m 2 at 3-week intervals. Cisplatin at a reduced dosage of 80 mg/ m 2 was used instead of 100 mg/m 2 , so that enrolled patients could complete the planned protocol design in clinical practice. Nevertheless, the completion rate was low.
The objective of this study was to elucidate the source of the low completion rate of cisplatin courses in our institute. Here, the results of our retrospective analysis of the protocol completion rate, the reasons for patients' discontinuation of the treatment and the limiting factors of this therapy are presented.
PATIENTS AND METHODS

PATIENT BACKGROUND
Between November 2007 and May 2010, at the Department of Otorhinolaryngology of Nagoya University Hospital, 28 patients with head and neck cancer were treated with curative intent according to the protocol for concurrent cisplatin chemotherapy with radiotherapy. All cancers were histologically diagnosed as squamous cell carcinoma. Eligibility for this protocol was as follows. The patients were required to be older than 20 years. They underwent a physical examination, blood examinations, chest radiographs, an electrocardiogram and a 24 h creatinine clearance test. They were also required to have adequate hepatic and renal function (creatinine clearance . 50 ml/min). The laboratory values needed to meet the following criteria: white blood cell count .4000/mm 3 , platelet count .100 000/mm 3 , serum creatinine ,1.5 mg/dl, hemoglobin .10 g/dl and bilirubin ,1.5 mg/dl. The patients were also required to have a performance status based on the Eastern Cooperative Oncology Group system of %1. Table 1 summarizes the clinical characteristics of the 28 patients who were included in this study. The patients, 25 males and 3 females, ranged in age from 39 to 77 years, with a median age of 63 years. The disease diagnosis was oropharyngeal cancer in 11 patients, hypopharyngeal cancer in 10 patients, laryngeal cancer in 3 patients, nasopharyngeal cancer in 2 patients, maxillary cancer in 1 patient and cancer of unknown origin in 1 patient. This analysis excluded patients who underwent chemoradiotherapy as postoperative adjuvant therapy and those who underwent chemoradiotherapy due to recurrence of nodal disease. All patients gave their written informed consent before starting treatment. This study was approved by the ethics committee at Nagoya University Hospital.
PROTOCOL DESIGN
The protocol used in this study consisted of concurrent cisplatin chemotherapy and radiotherapy. Radiotherapy was administered at 2 Gy/day, 5 days/week, starting on Day 1 and continuing until total doses ranging from 66 to 70 Gy were delivered. The entire neck was irradiated with 40 Gy. Thereafter, the portal was reduced at the primary site and clinically positive nodes to spare the spinal cord.
Meanwhile, chemotherapy consisting of three courses of cisplatin was administered every 3 weeks, beginning with radiotherapy on Day 1 and followed by administration of 80 mg/m 2 cisplatin on Days 22 and 43 of radiotherapy. Complete treatment delivery was defined as both administration of 66 -70 Gy and three courses of cisplatin during the radiotherapy.
Dose modification or discontinuation of cisplatin was based on not only renal function but also nadir blood counts and interim toxicities during the preceding course. For the first course of cisplatin, the dosage was adjusted on the basis of the 24-h pooled -urine creatinine clearance value. For the second and third courses, the creatinine clearance was estimated from the serum creatinine value using the Cockcroft -Gault formula. A 100% dose of cisplatin was administered when the creatinine clearance was 60 ml/min or more. When the creatinine clearance was at least 50 ml/min but ,60 ml/min, a 75% dose was administered, while a 60% dose was administered when the creatinine clearance was 40 ml/min or greater but 
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Hematotoxicity and serum albumin level ,50 ml/min. Cisplatin administration was discontinued when creatinine clearance dropped to ,40 ml/min. In order to reduce renal function damage by cisplatin, the patients were given aggressive hydration and antiemetic therapy around the time of cisplatin administration. To reduce nausea and vomiting, premedication consisting of a serotonin antagonist and dexamethasone (Decadron) was also given on Days 1 -5. After aprepitant (Emend) became commercially available in December 2009, it was also co-administered. With regard to the delay or discontinuation of cisplatin, the next planned administration was postponed in the case of a neutrophil count of ,1500 /mm 3 or a platelet count of ,100 000emsp14;/mm 3 and was resumed only after the neutrophil count recovered to at least 1500 /mm 3 . Radiotherapy was continued even during periods of postponement of cisplatin administration, if there was no normal tissue reaction such as confluent mucositis. No granulocyte colony-stimulating factor products were given prophylactically.
For patients with poor nutritional status, percutaneous endoscopic gastrostomy (PEG) tubes were recommended. Nine patients were considered to require a PEG before the start of treatment, but only six of them used PEG feeding during concurrent chemoradiotherapy. One of the remaining three patients was suspected to have stomach cancer at PEG tube placement. Another patient developed a gastric ulcer after he started using the PEG tube. The last patient underwent PEG tube placement but refused to use it and continued oral intake. One patient received total parenteral nutrition without PEG tube placement. In total, 21 patients (75%) started concurrent chemoradiotherapy with oral intake. Appropriate pain management was used for mucositis, including xylocaine gargle, morphine or oxycodone. Patients continued oral intake for as long as possible to preserve swallowing, but in order to maintain their nutritional status, they used a nasogastric tube when they became unable to obtain more than half of their caloric needs orally. Nutritionists supported the food form and contents.
INVESTIGATED PARAMETERS
The following parameters were investigated for each of the 28 patients: age, sex, weight on the day before cisplatin administration, actual radiation dose, cisplatin dosage and intervals between doses, and changes in hematological data. Adverse events were graded for severity in accordance with NCI -CTCAE (Ver. 4.0). The data for the completion rate are presented for the patients as a group and also for subgroups stratified by radiation dose.
In an attempt to identify the potential factors leading to prolonged neutropenia, PASW statistics 18 and multiple regression analysis were used to identify relationships between various factors and the neutrophil count at 3 weeks after cisplatin administration. Pearson's product-moment correlation coefficient was also used to investigate the relation between the pre-cisplatin serum albumin level and the neutrophil count at 3 weeks after cisplatin administration.
RESULTS
RADIATION DOSE
The total doses of radiation administered were 66 Gy in 14 (50%) patients, 70 Gy in 10 (36%) patients, 60 Gy in 3 (11%) patients and 30 Gy in 1 (4%) patient. The patients who were discontinued at 60 Gy had the following adverse events: grade 3 dermatitis in one patient, grade 4 mucositis in one patient and concurrent grade 4 dermatitis and mucositis in one patient. The one patient who was discontinued at 30 Gy underwent surgery because of a very poor tumor response.
DOSAGE OF CISPLATIN
The dosage of cisplatin was reduced in patients with insufficient renal function in accordance with the previously mentioned criterion. In the first course, 26 (93%) patients received a 100% dose of cisplatin, and the remaining 2 (7%) patients received a 75% dose. In the second course, 17 (61%) patients received a 100% dose of cisplatin, 5 (18%) patients received a 75% dose and 2 (7%) patients received a 60% dose. Finally, in the third course, eight (29%) patients received a 100% dose of cisplatin, and one (4%) patient received an 80% dose.
ADVERSE EVENTS AND THEIR GRADES
Adverse events were graded for severity in accordance with NCI -CTCAE (Ver. 4.0) ( Table 2 ). Grade 3 leucopenia was seen in five (17.9%) patients in the first course, six (25.0%) patients in the second course and one (11.1%) patient in the third course. Grade 3 neutropenia was seen in one (3.6%) patient in the first course, four (16.7%) patients in the second course and one (11.1%) patient in the third course. Grade 3 anemia was seen in one (3.6%) patient in the first course, three (12.5%) patients in the second course and no patients in the third course. There were no cases of grade 3 or higher thrombocytopenia. Throughout the treatment period, there were no hematological adverse events evaluated as grade 4 or higher.
With regard to renal dysfunction, no patients had a serum creatinine value greater than 1.5 mg/dl. However, prior to administration of the first course of cisplatin, 27 patients had a serum creatinine value ,1.0 mg/dl, and in 6 (22%) of these patients, the value had increased slightly to 1.0 -1.5 mg/dl at 3 weeks after cisplatin administration.
Grade 3 and grade 4 mucositis was seen in five (17.9%) and two (7.1%) patients, respectively. Grade 3 and grade 4 dermatitis was seen in three (10.7%) and one (3.6%) patient, respectively. Of the 21 patients who started concurrent chemoradiotherapy with oral food intake, nasogastric tubes were inserted into 10 patients during concurrent chemoradiotherapy. No treatment-related deaths occurred.
COMPLETION RATES FOR THREE COURSES OF CISPLATIN
Cisplatin was administered three times to 9 (32%) of the 28 patients during the period of radiotherapy, two times to 15 (54%) patients and only one time to 4 (14%) patients (Fig. 1A) . Cisplatin was administered only one time to four patients for the following reasons: a decrease in renal function in one patient, aspiration pneumonia in one patient, a decrease in liver function in one patient and inadequate efficacy in one patient. Cisplatin was administered only two times to 15 patients for the following reasons: neutropenia in 8 patients, a decrease in renal function in 3 patients, anemia in 2 patients, aspiration pneumonia in 1 patient, infection in 1 patient, thrombocytopenia in 1 patient, thrombosis in 1 patient and refusal to undergo chemotherapy in 1 patient. Of these reasons, two applied to three of these patients.
In 24 patients given a total radiation dose of 66 -70 Gy, 9 (37.5%) were given all three doses of cisplatin, while 13 (54%) were given two doses and 2 (8%) were given only one dose (Fig. 1B) . No patients were administered cisplatin after the radiotherapy had been completed.
MULTIPLE REGRESSION ANALYSIS OF NEUTROPENIA
Multiple regression analysis was performed for the 28 patients. The independent variables were as follows: age, sex, 24-h pooled urine creatinine clearance, serum Na, serum BUN, serum albumin, serum total bilirubin values prior to the first cisplatin course, and administered cisplatin dose (give as a percentage, with a total dose of 80 mg/m 2 defined as 100%). The dependent variable was the neutrophil count at 3 weeks after the first cisplatin administration. Only the serum albumin level (b ¼ 0.517, P , 0.01) was a significant explanatory variable (R 2 ¼ 0.664) for the neutrophil count at 3 weeks after the first cisplatin administration. Other factors (age, sex, 24-h pooled urine creatinine clearance, serum Na, serum BUN and serum total bilirubin) were not significant explanatory variables for the neutrophil count (P . 0.05).
RELATIONSHIP BETWEEN THE PRE-CISPLATIN SERUM ALBUMIN LEVEL AND NEUTROPHIL COUNT 3 WEEKS AFTER CISPLATIN ADMINISTRATION
For the 28 patients, the relationship between the serum albumin level prior to the first cisplatin course and the neutrophil count at 3 weeks after cisplatin administration was plotted ( Fig. 2A) . Pearson's product-moment correlation coefficient showed a strong correlation between these two parameters (r ¼ 0.605, P , 0.01). In addition, the relationship between the serum albumin level in the case of the 100% cisplatin dose and the neutrophil count at 3 weeks after cisplatin administration (for the first and second courses) was plotted (Fig. 2B ). After exclusion of two patients who developed infections, 41 pairs of variables were also analyzed, resulting in a strong correlation between these two parameters (r ¼ 0.595, P , 0.01).
RELATIONSHIP BETWEEN BODY MASS INDEX OR HEMOGLOBIN LEVEL AND NEUTROPHIL COUNT 3 WEEKS AFTER CISPLATIN ADMINISTRATION
Body mass index (BMI) and hemoglobin levels are commonly evaluated together with serum albumin. Thus, the relationship between BMI or hemoglobin level and neutrophil count at 3 weeks after cisplatin administration was investigated using Pearson's product-moment correlation coefficient. There was no relationship between BMI and the neutrophil count (r ¼ 0.277, P ¼ 0.15). However, there was a relatively strong relationship between the hemoglobin level and the neutrophil count (r ¼ 0.545, P , 0.01), but it was weaker than that between the neutrophil count and the serum albumin level. Furthermore, there was a strong relationship between the hemoglobin level and the serum albumin level (r ¼ 0.77, P , 0.01). The hemoglobin level and the serum albumin could not be used at the same time in the multiple regression analysis because they were not independent variables in this study, but the serum albumin level was the strongest parameter affecting the neutrophil count at 3 weeks after cisplatin administration.
DISCUSSION
Many clinical studies have reported the efficacy of concurrent chemoradiotherapy using cisplatin in the treatment of head and neck cancers. However, there have been few reports regarding the appropriate dosage of cisplatin and the treatment completion rate in Japanese patients. Zenda et al. [13] have proved the feasibility of 100 mg/m 2 , without modification of the cisplatin dosage, for Japanese patients. But, compared with the previous overseas reports [9 -11] , our patients were older (average age: 62.3 years). Additionally, it is known that Japanese patients have lower creatinine clearances with aging; so dose adjustment of cisplatin is important [14] . Many patients, nine patients (32.1%) in this study, had a creatinine clearance of less than 70 ml/min. Furthermore, our patients might have had poor nutritional status. Therefore, we gave cisplatin at a reduced dosage of 80 mg/m 2 , which were more suitable for our study population.
However, even at that dosage, not all patients could complete the planned protocol design. Our analysis of the 28 patients included in this retrospective study found that the actual completion rate for the three planned cisplatin courses was very low, at only 32%. In four of the patients, completion of the treatment regimen was not possible because the total radiation dose was reduced. Even for the remaining 24 patients who were exposed to the planned radiation dose of 66 -70 Gy, only 37.5% were able to complete all three cisplatin courses. The main reason was prolonged myelosuppression. Because our patients received cisplatin only while they were undergoing radiotherapy, they could not receive cisplatin three times when they had delay of the schedule. In order to improve the completion rate, it is of great importance to elucidate the tendency to develop prolonged neutropenia.
It is said that 90% of cisplatin is bound to albumin within 3 h after administration, and the free drug thus reaches a steady-state level [15] . The free cisplatin that is not bound to albumin is excreted from the kidneys [16] . For this reason, the amount of cisplatin that is bound to albumin greatly influences the area under the curve of cisplatin. Experiments were carried out in which the administration method and the dose rate of cisplatin were varied, and then the pharmacokinetics and adverse events were compared [17, 18] . The results of these experiments showed that the amount of free cisplatin decreased as the dose rate decreased, and there was a tendency for the incidence of adverse events to decrease. On the other hand, it has been shown that the half-life of cisplatin decreases when the serum albumin level is low [19] . In patients with a low serum albumin level, the cisplatin concentration in blood temporarily becomes high compared with the level in patients with normal albumin levels, and there may be a transient increase in the free cisplatin level in blood. The reason for adverse events during chemoradiotherapy with cisplatin may be the increased free cisplatin level in blood.
For our investigation of the factors that influence the neutrophil count at 3 weeks after administration of cisplatin, multiple regression analysis using the serum Na value as a variable was performed to exclude an apparent decrease in the blood cell count arising from edema.
Additionally, in order to exclude any influences arising from hepatic dysfunction and/or renal dysfunction, the analysis was carried out using the serum total bilirubin value, 24-h pooled urine creatinine clearance value and serum BUN value as variables. In the case of decreased renal function, cisplatin was administered at a reduced dosage in accordance with the criteria for dose reduction. This dose reduction method was shown to be appropriate. The only factor found to be associated with the neutrophil count at 3 weeks after cisplatin administration was the precisplatin serum albumin level. When the relationship between the pre-cisplatin serum albumin level and the neutrophil count at 3 weeks after cisplatin administration was plotted, strong correlations were seen for both the first and second cisplatin courses. These findings showed that there is prolonged neutropenia following cisplatin administration to patients with a reduced serum albumin level. Many patients with locally advanced cancer have low serum albumin levels. Therefore, it is important to maintain good nutritional status in order not to cause prolonged neutropenia.
Aprepitant became commercially available in December 2009, and beginning in mid-December, this drug was administrated to all of study patients. Prior to that time, 20 patients had received a radiation dose of 66-70 Gy; of these, 6 (30%) received all 3 courses of cisplatin therapy, 12 (60%) received 2 courses and 2 (10%) received only 1 course. On the other hand, of the four patients treated with aprepitant, three (75%) received all three courses of cisplatin and the remaining one (25%) patient received two courses. Although this sample size was small, the patients' appetite may have been better maintained after the start of this therapy due to the effects of aprepitant, which could have contributed to the maintenance of the serum albumin level at the time of the second cisplatin course.
Completion of treatment according to the treatment protocol is extremely important in order to achieve sufficient therapeutic efficacy. To that end, it is necessary to provide appropriate support to patients with the adverse events and to elucidate the potential factors that exacerbate adverse events. The present analyses demonstrate that the rate of completion of concurrent chemoradiotherapy in patients with head and neck cancers is low, that administration of cisplatin is delayed by a decrease in the neutrophil count and that there is a relationship between the serum albumin level and neutropenia. Many patients with locally advanced head and neck cancers are susceptible to a decline in nutritional status due to reduced food intake. Therefore, nutritional management before the cisplatin administration is important to complete the planned treatment. It is desirable to adopt an aggressive approach to instruction in nutrition, not only during the course of treatment but also before therapy is initiated. Higher completion rate can be expected by maintaining good nutritional status before and through concurrent chemoradiotherapy.
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